These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A specific cutaneous lesion revealing myelodysplastic syndrome. Kajisawa C; Matsui C; Morohashi M Eur J Dermatol; 1998; 8(7):517-8. PubMed ID: 9854168 [TBL] [Abstract][Full Text] [Related]
3. [Effective treatment of myelodysplastic syndromes-refractory anemia with excess blasts type II by decitabine: a case report]. Bao L; Huang XJ Zhonghua Xue Ye Xue Za Zhi; 2012 Jul; 33(7):573. PubMed ID: 22967422 [No Abstract] [Full Text] [Related]
5. Thalidomide abolishes transfusion-dependence in selected patients with myelodysplastic syndromes. Musto P; Falcone A; Sanpaolo G; Bisceglia M; Matera R; Carella AM Haematologica; 2002 Aug; 87(8):884-6. PubMed ID: 12161367 [No Abstract] [Full Text] [Related]
6. Lymphnode localization of extramedullary myeloid cell tumor in myelodysplastic syndrome: report of one case diagnosed by fine-needle cytology. Fulciniti F; Zeppa P; Marino G; Martinelli V; Ciancia R; Del Vecchio L; Rotoli B; Palombini L Diagn Cytopathol; 2003 Mar; 28(3):136-9. PubMed ID: 12619094 [TBL] [Abstract][Full Text] [Related]
7. An Unexpected Innocent Complication Associated with Azacitidine Treatment of Myelodysplastic Syndrome: Erythema Annulare Centrifugum. Turan Erkek E; Kalayoğlu Beşışık S Turk J Haematol; 2016 Mar; 33(1):81-2. PubMed ID: 27020727 [No Abstract] [Full Text] [Related]
8. [Arthritis in a case of myelodysplastic syndromes]. Mimura J; Ishikawa T; Yabe H; Nagai K; Nakayama S Rinsho Ketsueki; 1988 Dec; 29(12):2292-6. PubMed ID: 3246713 [No Abstract] [Full Text] [Related]
9. Myelodysplastic syndromes in childhood. Report of 21 patients from Italy and West Germany. Creutzig U; Cantù-Rajnoldi A; Ritter J; Romitti L; Odenwald E; Conter V; Riehm H; Masera G Am J Pediatr Hematol Oncol; 1987; 9(4):324-30. PubMed ID: 3439582 [TBL] [Abstract][Full Text] [Related]
10. Donor lymphocyte infusions for post-transplant relapse of refractory anemia with excess blasts and monosomy 7. Skinner R; Velangi M; Bown N Pediatr Blood Cancer; 2008 Mar; 50(3):670-2. PubMed ID: 17253642 [TBL] [Abstract][Full Text] [Related]
11. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia. Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346 [TBL] [Abstract][Full Text] [Related]
12. Intermediate-dose busulfan and cyclophosphamide as a conditioning regimen for bone marrow transplantation in a case of Fanconi anemia in myelodysplastic transformation. Maschan AA; Kryzanovskii OI; Yourlova MI; Skorobogatova EV; Pashanov ED; Potapova YE; Timonova LA; Bogatcheva NY; Samochatova EV; Roumjantzev AG Bone Marrow Transplant; 1997 Feb; 19(4):385-7. PubMed ID: 9051250 [TBL] [Abstract][Full Text] [Related]
13. A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes. Garcia-Manero G; Faderl S; Giles F; Thomas D; Cortes J; O'Brien S; Davis J; Kantarjian HM; Estey E Haematologica; 2002 Aug; 87(8):804-7. PubMed ID: 12161355 [TBL] [Abstract][Full Text] [Related]
14. [Danazol treatment of myelodysplastic syndromes]. Vicente J; Feliu J; Cebreiros I; González Barón M Med Clin (Barc); 1989 Sep; 93(7):277. PubMed ID: 2811503 [No Abstract] [Full Text] [Related]
15. Long-term remission obtained by intensive chemotherapy against a leukemic relapse and subsequent graft-versus-host disease following an allogeneic BMT in a patient with myelodysplastic syndrome. Azuno Y; Kamei S; Kaku K; Yoshida T; Oeda E; Nishimura M; Okafuji K; Takeuchi Y; Tanaka M; Oka Y; Hiroshige Y; Kaneko T Bone Marrow Transplant; 1996 Mar; 17(3):463-4. PubMed ID: 8704709 [No Abstract] [Full Text] [Related]
16. [Clinical, hematologic and developmental characteristics of myelodysplastic syndromes. Study of a group of patients with a long-term follow-up]. Di Giovanni S; Giallonardo P; Costa MP; Carducci P Recenti Prog Med; 1987 Feb; 78(2):63-8. PubMed ID: 3473582 [No Abstract] [Full Text] [Related]
17. Low dose cytosine arabinoside in the treatment of acute non-lymphocytic leukemias and myelodysplastic syndromes. Tambone Reyes M; Bonaccorso R; Gebbia V; Tinnirello D; Di Salvo V; Ciulla A; Di Marco P; Mansueto S; Citarrella P J Chemother; 1989 Jul; 1(4 Suppl):1276-8. PubMed ID: 16312864 [No Abstract] [Full Text] [Related]
18. [Successful treatment of refractory anemia with excess of blasts in transformation with cytarabine ocfosfate]. Takeuchi M; Kojima K; Takaba S; Isokawa M; Tanimizu M; Kimura F; Ohmoto E; Harada M Gan To Kagaku Ryoho; 1995 Jan; 22(1):141-4. PubMed ID: 7826071 [TBL] [Abstract][Full Text] [Related]
19. [Erythroderma disclosing transformation of refractory anemia with excess of blasts into lymphoblastic leukemia]. Bodokh I; Lacour JP; Perrin C; Rosenthal E; Garnier G; Pesce A; Ortonne JP Ann Dermatol Venereol; 1993; 120(4):303-4. PubMed ID: 8239380 [TBL] [Abstract][Full Text] [Related]
20. [Myelodysplasia and tuberculosis]. Ugo V; Ramon S; Delmer A; Cadiou M; Marie JP Bull Cancer; 1996 Jul; 83(7):548-52. PubMed ID: 8868942 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]